This trial will study how well TT-00420 works in treating patients with advanced cholangiocarcinoma, as well as assessing its safety.
4 Primary · 6 Secondary · Reporting Duration: From first study drug administration until the date of death from any cause, assessed up to 24 months
80 Total Participants · 4 Treatment Groups
Primary Treatment: TT-00420 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: